Crispr Therapeutics Ag - Common Shares (CRSP) closed at $49.99 on November 3, 2026, unchanged from the previous close, on volume of 1,219,049 shares (30-day average 1,424,656).
Data as of November 3, 2026.
Analysts’ Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Faeth Therapeutics (FTH)
TipRanks (Tue, 3-Nov 1:30 PM ET)
Crispr Therapeutics AG (CRSP) Receives a Rating Update from a Top Analyst
TipRanks (Tue, 3-Nov 8:04 AM ET)
Crispr Therapeutics AG (CRSP) Receives a Buy from Piper Sandler
TipRanks (Tue, 3-Nov 7:56 AM ET)
CRISPR Therapeutics’ Growing Casgevy Adoption and Near-Term Pipeline Catalysts Support a Buy Rating
TipRanks (Tue, 3-Nov 7:47 AM ET)
CRISPR Therapeutics GAAP EPS of -$1.15 misses by $0.15, revenue of $12.67M misses by $3.89M
Seeking Alpha News (Mon, 2-Nov 4:03 PM ET)
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
Globe Newswire (Mon, 2-Nov 4:01 PM ET)
Market Chameleon (Mon, 2-Nov 3:22 AM ET)
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
Globe Newswire (Mon, 2-Nov 8:00 AM ET)
CRISPR Therapeutics Announces Chief Financial Officer Transition
Globe Newswire (Mon, 19-Oct 4:05 PM ET)
Market Chameleon (Fri, 9-Oct 7:27 AM ET)
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Crispr Therapeutics Ag - Common Shares trades on the NASDAQ stock market under the symbol CRSP.
As of November 3, 2026, CRSP stock price was flat at $49.99 with 1,219,049 million shares trading.
CRSP has a beta of 1.97, meaning it tends to be more sensitive to market movements. CRSP has a correlation of 0.19 to the broad based SPY ETF.
CRSP has a market cap of $4.83 billion. This is considered a Mid Cap stock.
Last quarter Crispr Therapeutics Ag - Common Shares reported $13 million in Revenue and -$1.15 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.09.
In the last 3 years, CRSP traded as high as $91.10 and as low as $30.04.
The top ETF exchange traded funds that CRSP belongs to (by Net Assets): ARKK, ARKE, XBI, ARKG, IWM.
CRSP has underperformed the market in the last year with a return of -21.9%, while SPY returned +11.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CRSP shares. However, CRSP has outperformed the market in the last 3 month and 2 week periods, returning +4.2% and -0.1%, while SPY returned +1.2% and -1.6%, respectively. This indicates CRSP has been having a stronger performance recently.
CRSP support price is $48.11 and resistance is $51.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRSP shares will trade within this expected range on the day.
